Citius Pharmaceuticals (NASDAQ:CTXR) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of Citius Pharmaceuticals (NASDAQ:CTXR) from a hold rating to a sell rating in a report published on Monday, Zacks.com reports.

According to Zacks, “Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered in Cranford, New Jersey. “

Separately, Dawson James assumed coverage on Citius Pharmaceuticals in a research note on Friday, September 6th. They issued a buy rating and a $7.00 price target for the company.

Shares of CTXR stock opened at $0.57 on Monday. Citius Pharmaceuticals has a 52-week low of $0.42 and a 52-week high of $1.79. The firm has a market capitalization of $12.36 million, a PE ratio of -0.49 and a beta of 0.62. The stock has a fifty day simple moving average of $0.87 and a two-hundred day simple moving average of $1.06.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.14). Equities analysts anticipate that Citius Pharmaceuticals will post -0.61 earnings per share for the current fiscal year.

In other news, CEO Myron Z. Holubiak acquired 558,597 shares of the business’s stock in a transaction dated Friday, September 27th. The stock was purchased at an average price of $0.90 per share, for a total transaction of $502,737.30. Also, major shareholder Leonard L. Mazur acquired 2,234,700 shares of the business’s stock in a transaction dated Friday, September 27th. The shares were purchased at an average price of $0.90 per share, with a total value of $2,011,230.00. Company insiders own 58.52% of the company’s stock.

A hedge fund recently raised its stake in Citius Pharmaceuticals stock. Vanguard Group Inc. grew its position in shares of Citius Pharmaceuticals Inc (NASDAQ:CTXR) by 308.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 453,156 shares of the company’s stock after purchasing an additional 342,180 shares during the period. Vanguard Group Inc. owned approximately 2.05% of Citius Pharmaceuticals worth $444,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 2.83% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.

Featured Story: Equity Income

Get a free copy of the Zacks research report on Citius Pharmaceuticals (CTXR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.